Ginkgo Bioworks Holdings, Inc. (DNA) insider RSU vesting triggers tax share sale

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. officer Steven P. Coen reported compensation-related equity activity involving restricted stock units (RSUs) and Class A Common Stock. On March 13, 2026, he exercised RSUs covering 1,486 shares, converting them into the same number of Class A shares at a per-share price of $0.0000. Each RSU represents a right to receive one share of Class A stock, and the RSUs vest over time according to pre-set schedules.

On March 16, 2026, Coen sold 708 shares of Class A Common Stock at an average price of $6.7350 per share. A footnote explains these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock and RSUs, and that such “sell to cover” transactions do not represent discretionary trades. Following these transactions, Coen directly owns 9,099 shares of Class A Common Stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coen Steven P.

(Last) (First) (Middle)

C/O GINKGO BIOWORKS HOLDINGS, INC.

27 DRYDOCK AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ginkgo Bioworks Holdings, Inc. [ DNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/13/2026		M(1)		1,174	A	(1)	9,495	D
Class A Common Stock	03/13/2026		M(1)		312	A	(1)	9,807	D
Class A Common Stock	03/16/2026		S(2)		708	D	$6.735	9,099	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/13/2026		M(1)			1,174	(3)	(3)	Class A Common Stock	1,174	(1)	8,231	D
Restricted Stock Units	(1)	03/13/2026		M(1)			312	(4)	(4)	Class A Common Stock	312	(1)	3,755	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

3. The RSUs vest as follows: 25% of the underlying shares vested on May 1, 2024, then 36 equal monthly installments thereafter.

4. The RSUs vest as follows: 2/48ths of the underlying shares vested on May 1, 2024, then 46 equal monthly installments thereafter.

Remarks:

Chief Financial Officer

	/s/ Karen Tepichin, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Steven P. Coen report at Ginkgo Bioworks (DNA)?

Steven P. Coen reported exercises of restricted stock units and a related share sale. He converted 1,486 RSUs into Class A Common Stock and sold 708 shares in a tax-related transaction tied to equity vesting.

How many Ginkgo Bioworks (DNA) shares did Steven P. Coen sell and at what price?

Steven P. Coen sold 708 shares of Ginkgo Bioworks Class A Common Stock. The sale occurred at an average price of $6.7350 per share, generating cash specifically to satisfy tax withholding obligations from equity vesting.

Were Steven P. Coen’s Ginkgo Bioworks (DNA) share sales discretionary trades?

The filing states the 708-share sale was not discretionary. It explains the shares were sold solely to cover tax withholding obligations upon vesting of restricted stock and restricted stock units under the company’s equity incentive plans.

How many Ginkgo Bioworks (DNA) shares does Steven P. Coen hold after these transactions?

After completing the RSU exercises and the tax-related sale, Steven P. Coen directly holds 9,099 shares of Ginkgo Bioworks Class A Common Stock. This figure reflects his updated ownership position reported in the Form 4 filing.

What restricted stock unit activity did Ginkgo Bioworks (DNA) report for Steven P. Coen?

Steven P. Coen exercised restricted stock units representing 1,486 underlying shares of Class A Common Stock at a conversion price of $0.0000. Footnotes describe separate RSU vesting schedules beginning May 1, 2024 and continuing in monthly installments.

Why did Ginkgo Bioworks (DNA) use a sell-to-cover transaction for Steven P. Coen?

The company’s equity incentive plans allow tax withholding to be funded through sell-to-cover transactions. In this case, 708 shares were sold to satisfy Coen’s tax obligations triggered by vesting of restricted stock and restricted stock units.